Endomicroscopy and Crohn´s Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Purpose:
The main objective of this study is to determine endomicroscopic features of Crohn´s disease.
Background:
Crohn´s disease is an inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from anus to mouth, causing a wide variety of symptoms. Diagnosis is based on several histologic features including transmural pattern of inflammation, crypt abscesses and granulomas. Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging, enabling the endoscopist to obtain an "optical biopsy" of the gastrointestinal mucosa during the endoscopic procedure.
Scope:
In patients with Crohn´s disease.
| Condition |
|---|
|
Crohn´s Disease |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Confocal Laser Endomicroscopy in Patients With Crohn´s Disease |
- To determine endomicroscopic features of Crohn´s disease. [ Time Frame: October 2009 until May 2010 ] [ Designated as safety issue: Yes ]
- Comparison of CLE findings with conventional histology. [ Time Frame: October 2009 until May 2010 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 40 |
| Study Start Date: | October 2009 |
| Study Completion Date: | August 2011 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
Methods:
Patients underwent colonoscopy for the evaluation of Crohn´s disease. During the endoscopic procedure CLE will be performed.
Procedure:
The patient underwent colonoscopy. During the procedure the patient will receive intravenous fluorescein or topical mucosal staining with acriflavin or cresyl violet, followed by in-vivo CLE of the tissue. Confocal images are digitally saved and analyzed afterwards.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with Crohn´s disease.
Inclusion Criteria:
- Written informed consent
- Age 18-85 years
- Ability of subjects to understand character and individual consequences of clinical trial
- Subjects undergoing colonoscopy
Exclusion Criteria:
- Inability to provide written informed consent
- Severe Coagulopathy (Prothrombin time < 50% of control, Partial thromboplastin time > 50 s)
- Impaired renal function (Creatinine > 1.2 mg/dl)
- Pregnancy or breast feeding
- Active gastrointestinal bleeding
- Known allergy to fluorescein, acriflavin or cresyl violet
- Residing in institutions (e.g. prison)
Contacts and Locations| Germany | |
| Department of Medicine I, University of Erlangen-Nuremberg | |
| Erlangen, Germany, 91054 | |
| Study Director: | Markus F. Neurath | University of Erlangen-Nuremberg |
More Information
No publications provided by University of Erlangen-Nürnberg Medical School
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Markus F. Neurath, M.D., Ph.D., University of Erlangen-Nuremberg |
| ClinicalTrials.gov Identifier: | NCT01102855 History of Changes |
| Other Study ID Numbers: | HN-0002 |
| Study First Received: | April 12, 2010 |
| Last Updated: | August 10, 2011 |
| Health Authority: | Germany: Ethics Commission |
Additional relevant MeSH terms:
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |
ClinicalTrials.gov processed this record on May 21, 2013